Cobimetinib-impurities | Pharmaffiliates

cobimetinib

It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.. Reference standards of Cobimetinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below

stdClass Object
(
    [pname] => Cobimetinib - API Standards 
    [catalogue_number] => PA 56 64000
    [category_ids] => ,80,71,78,70,82,121,
    [chemical_name] => 
    [weight] => 531.31
    [form] => C21H21F3IN3O2
    [cas] => 934660-93-2
    [pslug] => 934660-93-2-cobimetinib-api-pa5664000
    [latest_product] => 0
    [linkproducts] => 1
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 56 64000

Cobimetinib - API Standards


  • Catalogue No.:PA 56 64000

  • CAS :

    934660-93-2

  • Molecular Formula : C21H21F3IN3O2

  • Molecular Weight : 531.31